Granted Patent B2

US 12,252,545 · App. 17/202,018 · Granted Mar 18, 2025

Inventors: Daniel Getts (Stow, MA); Yuxiao Wang (Belmont, MA)

Assignee: MYELOID THERAPEUTICS, INC.

C07K16/2896A61K40/17A61K40/24A61K40/31A61K40/4205A61K40/4224A61P35/00C07K14/70578C07K16/2863C12N5/0645C12N9/1205C12N15/87A61K2239/38A61K2239/48C07K2317/52C07K2317/622C07K2319/03

Abstract

Claims (51)

1. A pharmaceutical composition comprising:

(a) a population of mRNA-electroporated cells lacking a viral component or a plasmid component, wherein the mRNA comprises a sequence encoding a chimeric fusion protein (CFP) or a sequence encoding an antigenic peptide, wherein:

(i) at least 50% of the cells in the population of mRNA-electroporated cells are CD 14+;

(ii) less than 10% of the cells in the population of mRNA-electroporated cells are dendritic cells; and

(iii)

(A) at least 50% of the cells in the population of mRNA-electroporated cells are CCR2+ (CD192+), and CCR5+ (CD195+) and two or more of: CD63+, CD56 CD120a+ (TNFR1+) or CD120b+ (TNFR2+);

(B) less than 50% of the cells in the population of mRNA-electroporated cells express CD64 CD68, CD80, CD86, CD163, CD206, CD200R, CD31, CD71, CLEC9A, CD1C for AXL/SIGLEC6;

(C) when the mRNA comprises a sequence encoding a CFP and the population of mRNA-electroporated cells are in the presence of cells expressing a cell-surface antigen to which the CFP specifically binds, the population of mRNA-electroporated cells one or more cytokines selected from the group consisting of IL-1beta, TNFalpha, IFN-alpha, MIP-1alpha, IL-8, eotaxin, PIGF-1, CCL3, IL6 and IL10; and

(D) when the mRNA comprises a sequence encoding a CFP and the population of mRNA-electroporated cells are in the presence of GMCSF, IL-4 IL-10, TGFbeta TCM and/or MCSF, the expression of MHCI or MHCII is upregulated in the population of mRNA-electroporated cells to a greater extent compared to a corresponding population of cells that have not been electroporated with the mRNA; and

(b) a pharmaceutically acceptable excipient; and

wherein when the mRNA comprises a sequence encoding a CFP, the population of mRNA-electroporated cells in the pharmaceutical composition do not exhibit tonic signaling through the CFP ex vivo.

2. The pharmaceutical composition of claim 1 , wherein at least 50% of the cells in the population of mRNA-electroporated cells are CD16 low, CCR2+ and CCR5+.

3. The pharmaceutical composition of claim 1 , wherein at least 50% of the cells in the population of mRNA-electroporated cells are CD63+.

4. The pharmaceutical composition of claim 1 , wherein at least 50% of the cells in the population of mRNA-electroporated cells are CD56−, CD3−, and CD19−.

5. The pharmaceutical composition of claim 1 , wherein less than 40% of the cells in the population of mRNA-electroporated cells are macrophage cells.

6. The pharmaceutical composition of claim 1 , wherein:

(a) at least 50% of the cells in the population of mRNA-electroporated cells are CCR2+ and CCR5+;

(b) at least 50% of the cells in the population of mRNA-electroporated cells are CD63+;

(c) at least 50% of the cells in the population of mRNA-electroporated cells are CD56−, CD3−, and CD19−; and

(d) less than 40% of the cells in the population of mRNA-electroporated cells are macrophage cells.

7. The pharmaceutical composition of claim 1 , wherein the population of mRNA-electroporated cells are cultured for 48 hours or less.

8. The pharmaceutical composition of claim 1 , wherein the mRNA comprises a sequence encoding a CFP, wherein the CFP comprises:

(a) an extracellular domain comprising an antigen binding domain, and

(b) a transmembrane domain operatively linked to the extracellular domain.

9. The pharmaceutical composition of claim 8 , wherein the antigen binding domain is a GPC3 binding domain, a CD5 binding domain or a HER2 binding domain.

10. The pharmaceutical composition of claim 8 , wherein the CFP further comprises an intracellular domain, wherein the intracellular domain comprises a phosphoinositide 3-kinase (PI3K) recruitment domain, an intracellular domain from a phagocytic receptor, an intracellular domain from a scavenger receptor, an intracellular domain from CD16a, an intracellular domain from CD64, an intracellular domain from CD68, an intracellular domain from CD89, an intracellular signaling domain from FcγR, an intracellular signaling domain from FcαR, an intracellular signaling domain from FcεR, an intracellular signaling domain from CD40 or an intracellular signaling domain from CD3zeta.

11. The pharmaceutical composition of claim 8 , wherein the CFP comprises:

(a) an extracellular domain comprising:

(i) a scFv that specifically binds to CD5 or HER2, and

(ii) a hinge domain derived from CD8, or CD28 or an extracellular domain of CD68 or a portion thereof,

(b) a transmembrane domain from CD16a, CD64, CD68 or CD89; and

(c) an intracellular domain comprising at least two intracellular signaling domains, wherein the at least two intracellular signaling domains comprise

(i) a first intracellular signaling domain derived from CD3zeta, FcαR, FcγR or FcεR, and

(ii) a second intracellular signaling domain that:

(A) comprises a P13-kinase (PI3K) recruitment domain, or

(B) comprises an intracellular domain from CD40.

12. The pharmaceutical composition of claim 8 , wherein the transmembrane domain is a transmembrane domain from CD8, CD28, CD16a, CD64, CD68 or CD89.

13. The pharmaceutical composition of claim 8 , wherein the extracellular domain comprises an extracellular domain from CD8, CD16a, CD64, CD68 or CD89, or a fragment thereof.

14. The pharmaceutical composition of claim 8 , wherein the CFP comprises:

(a) an extracellular domain comprising:

(i) a scFv that specifically binds HER2, and

(ii) a hinge domain derived from CD8, or CD28 or an extracellular domain of CD68 or a portion thereof,

(b) a transmembrane domain from CD16a, CD64, CD68 or CD89; and

(c) an intracellular domain comprising at least two intracellular signaling domains, wherein the at least two intracellular signaling domains comprise

(i) a first intracellular signaling domain derived FcαR, FcγR or FcεR, and

(ii) a second intracellular signaling domain that:

(A) comprises a P13-kinase (PI3K) recruitment domain, or

(B) comprises an intracellular domain from CD40.

15. A method of treating a disease or condition in a subject in need thereof, comprising: administering the pharmaceutical composition of claim 1 to the subject.

16. The method of claim 15 , wherein the method comprises electroporating a population of cells with an mRNA comprising a sequence encoding a CFP or a sequence encoding an antigentic peptide, thereby forming the population of mRNA-electroporated cells, and wherein the pharmaceutical composition is administered to the subject within 72 hours after electroporating the population of cells with the mRNA.

17. The method of claim 16 , wherein the population of cells is from the subject.

Assignments (2)

Continuity (3)

References Cited (400)